Transce3nd LLC Takes $33,000 Position in Novo Nordisk A/S (NYSE:NVO)

Transce3nd LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 389 shares of the company’s stock, valued at approximately $33,000.

Several other large investors have also recently bought and sold shares of the business. Victory Capital Management Inc. raised its position in shares of Novo Nordisk A/S by 58.5% during the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company’s stock worth $5,410,000 after acquiring an additional 23,223 shares in the last quarter. Norman Fields Gottscho Capital Management LLC raised its holdings in Novo Nordisk A/S by 45.3% during the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after purchasing an additional 19,870 shares in the last quarter. Bryn Mawr Capital Management LLC boosted its holdings in shares of Novo Nordisk A/S by 358.8% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock valued at $3,346,000 after buying an additional 30,420 shares in the last quarter. Versant Capital Management Inc purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $86,000. Finally, Talbot Financial LLC acquired a new stake in Novo Nordisk A/S during the 4th quarter worth $4,066,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $59.89 on Wednesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The company has a market cap of $268.76 billion, a PE ratio of 18.20, a P/E/G ratio of 0.90 and a beta of 0.61. The stock has a fifty day moving average price of $74.67 and a 200 day moving average price of $90.76. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were paid a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date was Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is 49.54%.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on NVO shares. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 15th. Stifel Nicolaus cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Morgan Stanley started coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Finally, BNP Paribas assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an “underperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.